10月28日uSMART交易熱榜 | 看好美股反彈,指數ETF交易火爆
10月28日uSMART交易熱度排行榜

連續反彈3日後,週五(28日)港股再度重挫,前期在低位抄底的投資者也陸續減倉,兩倍做多恆科指ETF(7226)、盈富基金(2800)均見到資金流出。
美股週五上漲,受益於蘋果公司業績報告對科技股的提振,且少量經濟數據表明美聯儲對抗通脹的鬥爭取得了一些進展。投資者順勢加倉做多的ETF,減倉做空標的,3倍做多標普500(UPRO)以及TQQQ均上榜,1倍做空納斯達克(PSQ)、1倍做空標普500(SH)、3倍做空羅素2000(SRTY)以及SQQQ均有不同程度的拋售。此外,前期暴漲的3倍做空富時中國ETF開始遭到減持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.